Xenetic Biosciences, Inc. Cash Flow Statement
XBIO|13 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 13 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$3M
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Xenetic Biosciences, Inc. used $3M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$4.0M | -$4.1M | -$6.6M | -$5.6M | -$10.9M | -$12.8M | -$7.3M | -$3.6M | -$54.2M | -$12.5M | -$8.6M | -$129.7K | -$8.2K |
| Depreciation & Amortization | - | - | - | $0 | $1.0K | $4.2K | $15.8K | $23.8K | $36.4K | $56.1K | $52.0K | $104.6K | $19.5K |
| Operating Cash Flow | -$2.8M | -$4.1M | -$4.6M | -$4.7M | -$4.3M | -$6.4M | -$6.5M | $1.5M | -$8.8M | -$5.3M | -$6.1M | -$6.3M | -$313 |
| Capital Expenditures | - | - | - | - | - | - | - | $9.3K | $16.8K | $1.7K | $78.6K | $130.1K | $212.5K |
| Free Cash Flow | - | - | - | - | - | - | - | $1.5M | -$8.8M | -$5.3M | -$6.1M | -$6.4M | -$212.8K |
| FCF Margin | - | - | - | - | - | - | - | 19.6% | -293.5% | - | -613.1% | -2177.1% | -188.7% |